Pharmaceutical Research Transparency Act of 2023

HR 3160, the Pharmaceutical Research Transparency Act of 2023, requires drug manufacturers and clinical trial sponsors to publicly disclose detailed cost and research spending data. The bill mandates the NIH create a searchable online repository for clinical trial costs (including personnel, materials, per-patient expenses, and phase-specific breakdowns) that sponsors must submit within one year of trial completion. It also requires drug manufacturers to report R&D expenditures disaggregated by research stage (basic research, pre-clinical, phases I-III trials) in their SEC annual filings. These provisions directly affect drug manufacturers subject to SEC reporting and sponsors of clinical trials starting after the bill's enactment. The law aims to increase transparency around drug development costs without altering drug pricing or approval processes.